Clinical Research Career Development Program

描述(由申请人提供)：我们要求续订我们为达纳·法伯/哈佛癌症中心(DF/HCC)的高级研究员和初级教员提供的多学科K-12肿瘤学翻译研究培训计划。该计划于2002年首次获得资助，已经资助了来自不同专业背景(外科、医学、放射肿瘤学)和具有不同研究兴趣的14名研究员，以及由治疗补充剂资助的两名少数族裔研究员。。它的目标是培养下一代临床研究人员，他们在实验室科学、人口科学和临床医学之间工作。它强调分子肿瘤学的研究培训及其在临床医学中的应用。每个受训人员由两名导师指导，一名指导他们的实验室或流行病学调查，另一名指导他们的临床调查。受训者在补助金的最初两年时间里，追求他们工作的临床前部分，并获得第二个两三年阶段工作所需的临床研究的教学背景，这一阶段强调翻译部分的开发和启动。每个阶段的确切时间和内容取决于获奖者之前的培训情况和项目的性质。受训人员在整个任期内以这笔赠款的身份参加DF/HCC疾病计划。学者们在临床研究的方法、伦理和监管方面进行研究生培训。我们要求学者获得高级学位，如果还没有获得学位的话。许多学者是以实验室科学博士学位进入该项目的；他们的培训强调为临床研究做准备，以及在他们进一步从事实验室工作的同时负责任地进行研究。其他人主要来自临床背景，需要在实验室或流行病学方法方面进行密集的动手培训，并加强对癌症生物学的了解。我们K-12项目的所有11名毕业生目前都在DF/HCC研究机构或其他大学担任教职，目前的5名学者也是如此。所有毕业生都拥有独立的同行评议基金。导师是从哈佛医学院(HMS)和DF/HCC的资深教员的永久名单中挑选出来的。麻省理工学院大卫·科赫综合癌症研究中心的教师也担任导师，该中心主任泰勒·贾克斯作为我们咨询委员会的成员参加了会议。其他导师将根据需要添加到此列表中。哈佛医学院(HMS)、哈佛公共卫生学院(HSPH)和DF/HCC联盟医院的实验室可以接待K-12学者。学者可以使用广泛的临床试验系统(有500项活跃试验)和DF/HCC的19个核心设施，以及医院的研究中心和设施。候选人是从已完成肿瘤专业临床培训并具有至少两年进一步基础或临床研究经验的医生中挑选出来的。获奖者包括内科、放射和外科肿瘤学家，尽管由于强调药物开发，内科肿瘤学家占主导地位。K-12奖获得者是通过竞争激烈的DF/CC范围内的征集活动选出的，因为有空位可用，特别鼓励妇女和少数族裔候选人。我们的11名毕业生中有5名是女性，两名K-12学者得到了NCI提供的治疗补充剂的资助。一个咨询委员会由16名成员组成，其中包括5名妇女和2名少数民族调查人员，他们对临床和实验室研究以及学术职业发展有着不同的兴趣，从申请者中挑选受训人员。同一咨询委员会每半年审查一次候选人的进展情况，包括实验室和临床导师的报告，并建议改变导师、研究计划或实习生状态(从该计划毕业)。咨询委员会寻求培训方案主任和机构办公室对少数群体和妇女职业发展的投入，以增加我们申请者的多样性。在上一次拨款续签期间任命的六名新学者中，有两名是少数族裔科学家，他们通过K-12课程的少数族裔补充剂获得支持。少数族裔同伴指导计划预计将在未来的拨款期间增加少数族裔的申请。基于过去受训者在出版物和学术进步方面的显著记录，以及申请K-12补助金名额的优秀候选人的强大和不断增长，我们请求为这项补助金续期提供五个名额。

DESCRIPTION (provided by applicant): We request renewal of our multidisciplinary K-12 training program in translational oncology research for senior fellows and junior faculty of the Dana Farber/Harvard Cancer Center (DF/HCC). This program was first funded in 2002 and has supported 14 fellows from diverse subspecialty backgrounds (surgery, medicine, radiation oncology) and with diverse research interests, as well as two Minority Fellows funded by CURE Supplements. . Its objective is to produce a next generation of clinical investigators who work at the interface between laboratory science, population science, and clinical medicine. It emphasizes research training in molecular oncology and its application to clinical medicine. Each trainee is guided by two mentors, one for their laboratory or epidemiologic investigation, and a second mentor for their clinical investigation. Trainees spend the initial two years of service on the grant pursuing the preclinical component of their work and acquiring the didactic background in clinical investigation necessary for the second two-three year phase of their work, which emphasizes the development and initiation of the translational component. The precise timing and content of each phase depends upon the prior training of the awardee and the nature of the project. Trainees participate as members of DF/HCC disease programs throughout their tenure on this grant. Scholars pursue postgraduate training in the methods, and in the ethical, and regulatory aspects of clinical research. We require scholars to obtain an advanced degree if one has not already been obtained. Many scholars enter the program with PhD degrees in laboratory sciences; their training emphasizes preparation for clinical investigation and the responsible conduct of research even as they pursue further laboratory work. Others come from a predominantly clinical background and require intensive hands-on training in laboratory or in epidemiological methods and to enhance their understanding of cancer biology.. All eleven graduates of our K-12 program currently occupy faculty positions in DF/HCC research facilities or in other universities, as do all five of the current scholars. All graduates hold independent peer reviewed funding. Mentors are selected from a permanent list of senior faculty of Harvard Medical School (HMS) and the DF/HCC. Faculty at the David Koch Center for Integrative Cancer Research at the Massachusetts Institute of Technology have also served as mentors, and its Director, Tyler Jacks, participates as a member of our Advisory committee. Additional mentors are added to this list as needed. The laboratories of the Harvard Medical School (HMS), the Harvard School of Public Health (HSPH), and the DF/HCC consortium hospitals may host K-12 scholars. Scholar have access to the extensive clinical trials system (with 500 active trials) and the 19 core facilities of the DF/HCC, and to hospital research cores and facilities.. Candidates are drawn from the pool of physicians who have completed clinical training in an oncological specialty, and have at least two years of further basic or clinic research experience. Awardees include medical, radiation, and surgical oncologists, although, because of the emphasis on drug development, medical oncologists have predominated. K-12 awardees are selected through a highly competitive DF/HCC-wide solicitation as slots become available, with specific encouragement of women and minority candidates. Five of our eleven graduates have been women, and two K-12 scholars have been funded with CURE Supplements from NCI. An advisory committee, composed of 16 members, including 5 women and two minority investigators, with diverse interests in clinical and laboratory research and in academic career development, selects trainees from the applicant pool. The same advisory committee reviews the progress of the candidates, including reports from both laboratory and clinical mentors, on a semiannual basis, and recommends changes in mentorship, research program, or trainee status (graduation from the program). The advisory committee seeks the input of training program directors and institutional offices for minority and women's career development in order to increase the diversity of our applicant pool. Two of the six new scholars appointed during the last grant renewal were minority scientists supported through CURE Minority Supplements to the K- 12. A minority fellow mentoring program is expected to increase minority applications in future grant periods. Based upon the notable track record of publications and academic progress of past trainees, and the strong and growing pool of exceptional candidates for slots on the K-12 grant, we request five slots for the renewal of this grant.